Muscarinic agonists in Alzheimer's disease.
As therapeutic agents, M1 agonists in the short-term may palliate symptoms of AD and improve memory function. In the long-term, M1 agonists have the potential to modify the underlying pathophysiology of AD, and thereby prevent or retard the course of dementia.
Growdon
J H
JH
Department of Neurology, Massachusetts General Hospital, Boston 02114, USA.
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000209:etiology; D000682:Amyloid / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D006801:Humans; D018721:Muscarinic Agonists / Q000627:therapeutic use*; D010275:Parasympathetic Nervous System / Q000502:physiology
D000682:Amyloid; D018721:Muscarinic Agonists